Welcome to our dedicated page for Evotec news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec stock.
Evotec SE (NASDAQ: EVO; Frankfurt: EVT) is a life science company focused on drug discovery and development, and its news flow reflects ongoing activity across partnerships, platforms and biologics. Company updates frequently highlight progress in strategic collaborations, such as multi-target kidney disease programs with Bayer, protein degradation and neuroscience alliances with Bristol Myers Squibb, and technology-focused agreements with Sandoz.
Investors following EVO news can expect announcements on clinical and preclinical milestones, including the advancement of monoclonal antibody programs into Phase 2 trials and Investigational New Drug acceptances for molecular glue degraders. Evotec also reports on grants and global health initiatives, for example Gates Foundation support for Just - Evotec Biologics’ J.MD™ molecular design service to improve the developability and affordability of monoclonal antibodies for infectious diseases.
News from Just - Evotec Biologics often centers on biologics development, continuous manufacturing technologies and the evolution of its asset-lighter model. This includes transactions such as the sale of the Toulouse site to Sandoz combined with an indefinite license to Evotec’s continuous manufacturing platform, as well as updates on revenue growth with a broadened customer base.
Regular corporate communications also cover financial results, guidance updates, cost reduction initiatives and organizational changes, such as segment renaming to Discovery & Preclinical Development and senior leadership appointments in communications and investor relations. For readers tracking EVO stock, this news page provides a consolidated view of how Evotec’s partnerships, platforms and strategic transactions are progressing over time.
Boehringer Ingelheim, Evotec, and bioMérieux have formed a joint venture named Aurobac Therapeutics SAS to combat Antimicrobial Resistance (AMR). Funded by Boehringer with 30 million EUR and 5 million EUR each from Evotec and bioMérieux, the venture aims to develop new antimicrobials and diagnostics. AMR poses a significant global health threat, with antibiotic-resistant infections causing around 1.27 million deaths annually. Aurobac seeks to implement precision medicine approaches and new economic models to enhance treatment strategies.
Evotec SE held its virtual Annual General Meeting (AGM) on June 22, 2022, with 65.68% of registered shareholders participating. All agenda items were adopted, including the election of Camilla Macapili Languille to the Supervisory Board, succeeding Kasim Kutay. The AGM approved the creation of Authorized Capital 2022 amounting to 20% of the share capital and a revised remuneration system for the Management Board, receiving 94.48% approval. The meeting also reaffirmed BDO AG as auditors for the fiscal year 2022.
Exscientia announced positive results from its Phase 1 healthy volunteer study of EXS-21546, a selective A2A receptor antagonist. The study confirmed potency and selectivity with low CNS exposure, supporting a Phase 1b/2 study in patients with high adenosine signature solid tumors, anticipated to start in the second half of 2022. The trial showed dose-dependent effects and was well-tolerated, with only one serious adverse event recorded that resolved without intervention. These findings enhance the potential for EXS-21546 to improve immunomodulatory treatments in cancer therapy.
Evotec SE has announced a strategic drug discovery collaboration with Janssen Pharmaceutica NV to explore novel therapeutic candidates via its TargetAlloMod platform. This partnership aims for high-potential cell surface drug targets within various therapeutic areas. Besides research funding, Evotec stands to gain approximately €210 million per project in success-based milestones and tiered royalties on resultant products. The collaboration highlights Evotec's innovative strengths and commitment to delivering effective therapeutics.
Evotec has announced the acquisition of Rigenerand Srl, a leading cell technology company, for €23 million. This move enhances Evotec's cell therapy platform by integrating high-quality cGMP manufacturing capabilities. Rigenerand, based in Italy, operates a state-of-the-art facility focused on cell therapy manufacturing. While initial revenue contributions are expected to be modest, the acquisition will strengthen Evotec's capabilities to secure new partnerships in the cell therapy sector. Both companies aim to leverage their combined expertise to advance innovative cell therapies.
Evotec and Almirall have formed a strategic multi-target alliance focusing on severe skin diseases including atopic dermatitis and basal cell carcinoma. This collaboration combines Evotec's advanced AI/ML-driven iR&D platform with Almirall's expertise in medical dermatology. Evotec will handle drug discovery and pre-clinical development, while Almirall will oversee clinical development and marketing. The deal includes an undisclosed upfront payment, potential milestone payments of up to €230 million per program, and royalties on net sales.
Evotec SE has announced the extension and expansion of its partnership with Bristol Myers Squibb in the field of targeted protein degradation, originally established in 2018. This eight-year extension aims to develop a robust pipeline of molecular glue degraders. Evotec will utilize its EVO panOmics and EVO panHunter platforms for this endeavor. The company has received an upfront payment of $200 million, with potential total deal value reaching $5 billion, including additional royalties on product sales.
Evotec SE announced an 8-year extension and expansion of its strategic partnership with Bristol Myers Squibb, initially signed in 2018, to develop a pipeline of molecular glue degraders. The collaboration, leveraging Evotec's EVO panOmics and EVO panHunter platforms, includes an upfront payment of $200 million, with the potential for total deal value reaching $5 billion through performance-based payments and royalties on product sales.
Evotec SE will announce its financial results for Q1 2022 on May 11, 2022. A conference call will follow the announcement, providing updates on performance, scheduled for 2:00 PM CEST. Participants can dial in from various countries, including the USA (+1 877 423 0830) and UK (+44 20 3009 2470). An audio webcast will also be available on the company's homepage shortly before the event. Evotec focuses on developing effective therapeutics through innovative technologies, partnering with top pharmaceutical companies and over 800 biotechnology firms.
Evotec SE reported a 23% increase in group revenues for the fiscal year ended December 31, 2021, reaching €618.0 million. Adjusted EBITDA rose to €107.3 million, up 1% from the previous year. The company achieved significant operational milestones, including expanded partnerships and clinical progress. It holds a robust liquidity position with €858.2 million in cash. For 2022, Evotec expects revenues between €700 - 720 million and plans to invest €70 - 80 million in unpartnered R&D to support ongoing growth initiatives.